GEOFFREY PLUMLEE: Open Payments
NPI 1538133640 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$51,014 in 306 payments from 27 companies in 2025. Trend: 2023 $37,051 · 2024 $55,425 · 2025 $51,014
Consulting: $46,000Food & beverage: $4,939Education: $75
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $46,113 |
| AstraZeneca Pharmaceuticals LP | 25 | $701 |
| ABBVIE INC. | 49 | $533 |
| Corium, LLC | 21 | $389 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 16 | $324 |
| Novo Nordisk Inc | 20 | $319 |
| Axsome Therapeutics, Inc. | 11 | $309 |
| PFIZER INC. | 18 | $308 |
| GlaxoSmithKline, LLC. | 25 | $303 |
| Lilly USA, LLC | 11 | $274 |
Products named: REXULTI, Azstarys, FARXIGA, JARDIANCE, Auvelity, TRELEGY ELLIPTA, LINZESS, CAPLYTA.
Industry payments across OK — which companies pay providers there.
